Portal de Periódicos da CAPES

Survival of adults with primary malignant brain tumours in Europe; Results of the EUROCARE-5 study

2015; Elsevier BV; Volume: 51; Issue: 15 Linguagem: Inglês

10.1016/j.ejca.2015.07.032

1879-0852

Otto Visser, Eva Ardanáz, Laura Botta, Milena Sant, Andrea Tavilla, Pamela Minicozzi, Monika Hackl, N. Zielonke, Willi Oberaigner, E. Van Eycken, K. Henau, Z. Valerianova, Nadya Dimitrova, Mario Šekerija, Miroslav Zvolský, Ladislav Dušek, Hans H. Storm, Gerda Engholm, Margit Mägi, Tiiu Aareleid, Nea Malila, Karri Seppä, Michel Velten, X. Troussard, Véronique Bouvier, Guy Launoy, A.V. Guizard, Jean Faivre, Anne‐Marie Bouvier, P. Arveux, M. Maynadié, Anne‐Sophie Woronoff, Michel Robaszkiewicz, Isabelle Baldi, Alain Monnereau, Brigitte Trétarre, Nadine Bossard, Aurélien Belot, Marc Colonna, F. Molinié, S. Bara, C. Schvartz, B. Lapôtre‐Ledoux, Pascale Grosclaude, M. Meyer, Roland Stabenow, Sabine Luttmann, Andrea Eberle, Hermann Brenner, Alice Nennecke, Jutta Engel, G. Schubert-Fritschle, Joachim Kieschke, Jan Heidrich, Bernd Holleczek, Alexander Katalinic, Jón G. Jónasson, Laufey Tryggvadóttír, Harry Comber, Guido Mazzoleni, A. Bulatko, Carlotta Buzzoni, Adriano Giacomin, A. Sutera Sardo, Pamela Mancuso, Stefano Ferretti, Emanuele Crocetti, Adele Caldarella, Gemma Gatta, Milena Sant, H. Amash, C. Amati, Paolo Baili, Franco Berrino, S. Bonfarnuzzo, Laura Botta, F. Di Salvo, Roberto Foschi, C. Margutti, E. Meneghini, Pamela Minicozzi, Annalisa Trama, Diego Serraino, Luigino Dal Maso, Roberta De Angelis, M. Caldora, Riccardo Capocaccia, E. Carrani, Silvia Francisci, Sandra Mallone, Daniela Pierannunzio, P. Roazzi, Silvia Rossi, Mariano Santaquilani, Andrea Tavilla, Fabio Pannozzo, S. Busco, L Bonelli, Marina Vercelli, Valerio Gennaro, Paolo Ricci, M. Autelitano, Giorgia Randi, Maurizio Ponz de Leòn, C. Marchesi, Claudia Cirilli, Mario Fusco, M.F. Vitale, M. Usala, A. Traina, R. Staiti, Francesco Vitale, Barbara Ravazzolo, Maria Michiara, ­Rosario ­Tumino, Paolo Giorgi Rossi, E. Di Felice, Fabio Falcini, Antonio Iannelli, O. Sechi, R. Cesaraccio, Silvano Piffer, A Madeddu, F. Tisano, S. Maspero, A.C. Fanetti, Roberto Zanetti, Stefano Rosso, P. Candela, T. Scuderi, Fabrizio Stracci, Fortunato Bianconi, Giovanna Tagliabue, Paolo Contiero, Angelo Paolo Dei Tos, Stefano Guzzinati, Santa Pildava, Giedrė Smailytė, Neville Calleja, D. Agius, T.B. Johannesen, Jadwiga Rachtan, Stanisław Góźdż, Ryszard Mężyk, Jerzy Błaszczyk, Marek Bębenek, Magdalena Bielska‐Lasota, G. Forjaz de Lacerda, María José Bento, Clara Castro, A. Miranda, A. Mayer-da-Silva, Florian Nicula, Daniela Coza, C. Safaei Diba, Maja Primic‐Žakelj, E. Almar, C. Ramírez, M. Errezola, J. Bidaurrazaga, A. Torrella-Ramos, J.M. Díaz García, R. Jimenez-Chillaron, Rafael Marcos‐Gragera, À. Izquierdo, María‐José Sánchez, D.Y.L. Chang, Carmen Navarro, María‐Dolores Chirlaque, C. Moreno-Iribas, Eva Ardanáz, Jaume Galcerán, M. Carulla, Mats Lambe, S. Khan, Seyed Mohsen Mousavi, Christine Bouchardy, M. Usel, S.M. Ess, H. Frick, Matthias Lorez, S.M. Ess, C. Herrmann, Andrea Bordoni, Alessandra Spitale, Isabelle Konzelmann, Otto Visser, Rob H.A. Verhoeven, Michel P. Coleman, Claudia Allemani, Bernard Rachet, Julia Verne, N. Easey, Gill Lawrence, Teresa Morán, Jem Rashbass, M. Roche, J. Wilkinson, Anna Gavin, David Donnelly, David Brewster, Dyfed Huws, Peter D. White, R. Otter,

Management of metastatic bone disease

Primary malignant brain tumours are rare but represent a serious health burden due to their poor survival. This manuscript describes the survival of malignant brain tumours in adults diagnosed 2000-2007 in Europe.For this study we analysed patients archived in 86 European population-based cancer registries, followed up to 31st December 2008. Only primary malignant neuroepithelial brain tumours (with pathological confirmation) and primary malignant unspecified brain tumours without pathological confirmation were included. We estimated 1-year and 5-year relative survival (RS) weighted by age group and country. We also estimated country-specific and age-specific survival, together with survival differences between time periods (for 1999-2001, 2002-2004 and 2005-2007).Glioblastoma represents 49% of all brain tumours, followed by other/unspecified astrocytoma (18%), oligodendroglioma/oligoastrocytoma (9%), ependymoma (1.5%) and embryonal tumours (1%). Five-year RS was 20% for all tumours combined, but ranged from 58% for ependymoma to only 6% for glioblastoma and sharply decreased with increasing age. Differences between countries were relatively small, but generally RS in Ireland/United Kingdom (UK) and Eastern Europe was below the average. An increase in 1-year RS (up to 10-12%) was noted over time, being largest in Central and Northern Europe in patients between 45 and 74years of age.Despite an increase in 1-year RS in most European regions, the survival of primary malignant brain tumours is still poor. Disparities between countries were evident, being even larger at the end of the study period than at the beginning, suggesting differences in availability of the latest treatment modalities.